Optimized LNP/nanogel vectors, specifically designed for Cas9 RNPs, utilize stimuli-responsive cationic lipids to achieve highly efficient, low-toxicity nuclear delivery by promoting endosomal escape, ensuring the highest instantaneous editing efficiency.
Targeting Delivery for Gene Editing
Gene editing technology represents the highest precision in biomedicine, offering the potential for curative therapies. However, its clinical safety and effectiveness depend entirely on whether the editing tool can reach the target gene locus in the most efficient and precise way. Creative Biolabs' targeted delivery technology focuses on overcoming the challenges of efficiency and safety in gene editing tool delivery, helping you achieve "precise rewriting" of the genome.
Click Here to View more about our Service
LNP-based Delivery System Development Services Cationic Liposomes Development Services for RNA Delivery Nucleic Acid Encapsulation Service
What is Targeted Delivery?
Targeted delivery here specifically refers to the safe, efficient, and cell-specific delivery of the core components of a gene editing tool—such as the Ribonucleoprotein (RNP) complex—into the nucleus of the target cell. This process requires navigating complex biological barriers, including endosomal entrapment, before cargo release. Ensuring the instantaneous presence and effectiveness of the editing tool in the target cell minimizes off-target editing and systemic immune responses, establishing the core strategy for achieving safe and therapeutic gene modification.
Applications for Gene Editing
Precision Treatment of Genetic Diseases
Delivering high-fidelity Cas9 RNP complexes via optimized nanovesicles for in vivo or in vitro knockout or precise correction of disease-causing genes. This includes successful non-viral editing of hepatic genes, such as permanent PCSK9 correction for hypercholesterolemia.
Universal Cell Therapy Manufacturing
Utilizing advanced non-viral vector solutions to deliver gene editing tools for in vitro knockout of endogenous TCR or HLA genes, accelerating the development of universal products such as CAR-T/TCR-T with enhanced scalability.
Base & Prime Editing
Facilitating the delivery of complex, large-sized editing proteins and gRNAs. This enables more precise single-base mutation repair, advancing therapies that require highly localized, transient editing and avoiding unintended double-strand breaks.
Fig.1 Illustration of nanovesicle types for gene editing components delivery.1
Delivery Challenges of Gene Editing
Off-Target Editing & Safety: Prolonged intracellular residence time (e.g., from long-term expression of delivered mRNA) or non-specific delivery of editing tools increases the risk of off-target editing and potential genotoxicity or tumorigenesis.
Efficient Delivery of Large-Molecular RNPs: Cas9 nuclease is a large protein molecule. Efficiently and intactly delivering it to the cell nucleus after forming an RNP complex with gRNA presents a significant delivery challenge, particularly the critical hurdle of endosomal escape.
In vivo Targeting & Immunogenicity: Viral vectors (such as AAV) pose risks of immunogenicity and sustained expression when delivering the Cas9 gene in vivo. Conversely, the in vivo efficiency and specific tissue tropism of untargeted non-viral vectors (LNPs) still require sophisticated surface optimization.
What We Can Offer
We offer professional targeted delivery technologies via our proprietary platform, focusing on solving the challenges of efficiency, safety, and precision in gene editing:
Ultra-Efficient RNP Delivery Platform
In vitro Cell Engineering Optimization
Providing customized electroporation or non-viral vector solutions to optimize RNP delivery for challenging cells like T cells, NK cells, and hematopoietic stem cells, facilitating the universalization of cell therapy.
In vivo Targeted Delivery Innovation
Optimized vector surface modification, including the use of aptamers for receptor-mediated endocytosis, enables precise targeting of non-hepatic organs such as the nervous system and muscles, expanding the application scope of in vivo gene editing.
Editing Efficiency & Safety Assessment
Provides full-process support, including RNP activity detection, off-target analysis, and editing efficiency verification, ensuring high precision and low toxicity in editing.
Why Choose Us?
Proven Precision
Our platform is built on virus-mimetic design, ensuring maximum RNP stability and targeted delivery.
Translational Focus
We address the two major clinical hurdles: off-target risk (via RNP and transient action) and poor non-hepatic tropism (via targeted ligands).
Full Support
We provide end-to-end expertise, from custom chemistry to efficiency and safety verification.
Scalability
Non-viral systems offer faster, more cost-effective manufacturing than traditional AAV vectors.
Workflow
Ready to accelerate your therapeutic pipeline? Contact us today to discuss a custom-engineered delivery solution and turn the promise of gene editing into patient reality.
Reference
- Kim, Dongyoon, et al. "Nanovesicle-mediated delivery systems for CRISPR/Cas genome editing." Pharmaceutics 12.12 (2020): 1233. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/pharmaceutics12121233
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
